Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.38 |
| ▸ | PLK4 | O00444 | 3/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.35 |
| ▸ | PAK4 | O96013 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7531677 | 0.83 | SMN1; SMN2 (0.40) | GAABCDIN3DMAPT | |
| SCHEMBL7531237 | 0.79 | SMN1; SMN2 (0.44) | P2RX7 | |
| SCHEMBL7533638 | 0.74 | — | — | |
| SCHEMBL7532592 | 0.74 | ADRA2C (0.39) | GAABCDIN3D | |
| SCHEMBL31137190 | 0.69 | KDM4E (0.40) | P2RX7NTRK1 | |
| SCHEMBL7530709 | 0.68 | CA12 (0.41) | GAAMAPT | |
| SCHEMBL7530442 | 0.66 | KMT2A (0.41) | GAABCDIN3DMAPT | |
| SCHEMBL7894092 | 0.65 | GAA (0.40) | GAAP2RX7PLK4NTRK1 | |
| SCHEMBL7531156 | 0.65 | NMT1 (0.41) | BCDIN3DMAPT | |
| SCHEMBL7527986 | 0.64 | NUDT1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032198-A1 | Diaminopyrazoles | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-14 | — | — | US | claimed |
| US-6319941-B1 | TREATMENT OF SMOOTH MUSCLE SPASTICITY OR EXCESS MUSCLE CONTRACTION SUCH AS URGE URINARY INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION | 2001-11-20 | — | — | US | claimed |
| US-6458823-B1 | 4,5-DIAMINO DERIVATIVES OF (1H)- PYRAZOLES AND THEIR USE IN THE TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION, WHICH INCLUDE, URINARY INCONTINENCE, HYPERTENSION, ASTHAMA, PREMATURE LABOR, IRRITABLE BOWL SYNDROM | WYETH | 2002-10-01 | — | — | US | disclosed |
| US-20020032198-A1 | Diaminopyrazoles | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-14 | — | — | US | disclosed |
| US-6319941-B1 | TREATMENT OF SMOOTH MUSCLE SPASTICITY OR EXCESS MUSCLE CONTRACTION SUCH AS URGE URINARY INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION | 2001-11-20 | — | — | US | disclosed |
| US-6313149-B1 | Diaminopyrazoles | AMERICAN HOME PRODUCTS CORPORATION | 2001-11-06 | — | — | US | disclosed |
| US-6172222-B1 | Diaminopyrazoles | AMERICAN HOME PRODUCTS CORPORATION | 2001-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032198-A1 | Diaminopyrazoles | ODC1, AOC1, CLIC1 | GAA 3304/4885BCDIN3D 1405/4885P2RX7 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.